Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer

Evaluation committee members

This topic was considered by the lead team of the highly specialised technologies committee, which includes the chair and vice chair.

Committee members are asked to declare any interests in the technologies being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

Chair

Paul Arundel
Chair, highly specialised technologies evaluation committee

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager and an associate director.

Tom Palmer
Technical lead

Zoe Charles
Technical adviser

Leena Issa
Project manager

Ian Watson
Associate director

ISBN: 978-1-4731-6840-4